Introduction
In an accompanying editorial review, 1 we discussed the problems of how trough and peak (T:P) responses to antihypertensive drugs have been defined using ambulatory blood pressure monitors (ABPM). In this paper we address further problems related to the population in which these estimates should be done and how the data should be handled.
A T:P ratio of 0.8 related to a drug or a particular dose of a drug has little meaning without knowledge of the variance. 2 If this is small, there is a reasonable probability that BP will be maintained for 24 h (or other dose interval) in most patients with the given dose. If the variance is large the ratio may not apply to an individual patient. This is particularly likely with drugs that have variable bioavailability or a shallow dose-response curve. With such drugs the variance for any particular dose is likely to be so large that it is not possible to apply the results to an individual, and thus the T:P ratio has little clinical meaning. Instead of the ratio, it may be preferable to measure the peak and trough fall in BP and calculate the difference between them. This would provide the magnitude of the peak response that did not persist for 24 h.
It will be argued that T:P ratios should be determined in people who respond to a drug at time of peak effect, that the ratio should be calculated for each individual and that the ratio should be determined for different doses of the drug.
Individuals or group?
To avoid difficulties in data handling the T:P ratio has usually been determined for a defined group of Correspondence: Dr T Morgan, Department of Physiology, University of Melbourne, Parkville, Australia Received 2 February 1997; revised and accepted 7 July 1997 patients. Two common approaches have been used with ABPM. In one, the group's BP profile on placebo and drug has been plotted using one or two hourly means, the peak fall has been defined as the maximum fall over a one or two hourly interval and the trough as the fall in the 23rd and 24th hour. 3 This technique probably gives a reasonable estimate of peak (as false peak responses are avoided) but the trough estimate will be inaccurate because of the inclusion of sleeping BP, bearing in mind that medication is usually taken at 8.00 am and the trough is from 6.00-8 am. No statistics can be applied to these results.
The second approach has been to determine the peak and the trough response for an individual, 4 and whether they are different from zero and each other. However, when the ratio is calculated from the group mean changes no statistics can be applied. Thus it is impossible to compare statistically data from different studies or to determine if a ratio of 0.8 is different from 0.4 or even from 0.0. The absence of a variance for the T:P ratio seriously limits the usefulness of the data.
The alternative and preferred approach 5 is to calculate individual ratios, but in most studies performed in ambulant patients during normal activity the within-subject variability in BP from one day to another creates much 'noise' that mean values are misleading and the data can only be handled by median values. 6, 7 Even this is flawed. Some problems are as follows: (1) a fall at trough but no fall at peak to give a ratio of infinity; (2) changes in BP in opposite directions at trough and peak, giving negative values; and (3) a rise in BP at trough and peak giving a positive but meaningless value. Thus a ratio of 0.8 could be a fall at peak of 20 mm Hg with a fall at trough of 16 mm Hg or an increase at peak of 5 mm Hg with an increase at trough of 4 mm Hg. Pooling such ratios provides complex or nonsensical descriptive statistics.
Elliott and Meredith 5 state that under carefully controlled conditions, all (or most) patients have a fall in BP at peak, which they define under their conditions as the placebo corrected maximal fall. Thus the problems alluded to above do not exist, provided that if there is a rise at trough they call this no response (ie, 0 mm Hg) and define a T:P ratio of zero. When ABPM is deployed under the more usual circumstances, rises in BP may be seen at a time when a fall would be predicted since spontaneous BP variability is often greater than the drug effect. These problems can be avoided in part by measuring the effect in responders, and avoiding BP taken at times of major spontaneous variation.
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Responders or all patients?
The data that is important for clinical practice is related to the predictability of the hypotensive action of the drug. If a patient does not respond, whether this is assessed at trough or peak, the doctor will stop the drug. However, if there is no response at trough this may be because the duration of action is short (or the dosage interval is too long); ie, the drug has a low T:P ratio. If such a drug is used and BP is titrated using trough responses there is a risk that the ultimate dose used will be excessive. If there is a response at peak it is important to know the ratio because only if the T:P is Ͼ0.7 will the response be adequate at trough. Including data from people who have no or a very small response increases the uncertainty of the T:P ratio as the values are sensitive to very small changes in BP. This is not an insurmountable problem if group means are used to calculate T:P but is a major random problem when ratios are calculated individually as the ratios fluctuate widely and a logarithmic transformation would be needed for statistical analysis. The efficacy of a drug needs to be determined in unselected patients but the T:P ratio is not a measure of efficacy and is only relevant for responders. An ABPM in an individual patient can detect a difference of 5 mm Hg and if there are 12-16 readings such a difference can be detected over a 3-4 h interval. 8 We suggest that responders should be identified arbitrarily as those with a fall in BP of 5 mm Hg or more between 3 and 6 h after drug administration. Some people who are not true responders may be included by this definition. We suggest that the ratio should be calculated only in patients with this level of response. It is important to use a fixed time interval and a reasonable time period (4 h) to minimise the risk of including spurious responders. The other criterion that needs to be applied is to assign a value of 0.0 if the BP at trough is higher than on the placebo day, and a value of 1.0 if the effect at 'trough' is greater than at 'peak'. As we have called the value 0.0 above we should probably include such values at 1.0. All ratio values will then lie between 0.0 and 1.0.
The question arises whether the responders can or should be identified in the same study as the T:P is measured. 9 Purists might claim that responders should be identified in an initial study and the T:P determined in a subsequent study. 10 The problem in that situation is the design of the initial study. It cannot be one in which the drug is titrated at trough because if the T:P ratio is close to zero for an individual patient, that person would be identified as a non-responder rather than a responder with a ratio close to 0. Thus the initial study must have ABPM performed (or alternatively measure the BP at the clinic at the time of peak response) on both placebo and active agent. This person must then undergo a further study in which placebo or active drug are given. While statistically this represents the best approach it ignores the comfort of the patient.
The following approach is suggested. Patients with hypertension, preferably defined on both clinic and ABPM, should be entered into a single study, ideally a randomised crossover study of placebo and active agent. The drug dose is titrated based on the clinic BP at trough until a satisfactory response is obtained or the maximum dose is reached. An ABPM is performed. Patients are divided into responders based on the pre-determined definition and the T:P ratio is calculated for this group of patients using individual calculations. This process will provide a T:P ratio greater than 0.0 and whether it is greater than some pre-defined acceptable limiting value. This will give a value for a drug, rather than a particular drug dose, in an individual patient based on trough titration. This value may not be the same as the corresponding ratio when measured at peak.
T:P of individual doses of a drug
Because patients generally attend their doctors during the day, antihypertensive drugs are usually titrated close to peak. 10 In this circumstance, there may appear to be an adequate response which may not persist and be present at trough. 11 If a drug at usual doses has a relatively linear relationship between plasma concentration and BP response (as exists for the dihydropyridines 12 ), the T:P ratio is similar at these doses. 13 However, if a drug has a relatively narrow dose response relationship and then reaches a plateau, the effect will be different and the T:P is dose-dependent (Figure 1) . When titrated at peak a drug dose will be reached just at the top of the dose response curve and prior to the next dose it will descend the curve and if the halflife is short, reach a level where the effect is less than desired. When titrated based on BP at trough, the same blood concentration is reached at the end of the dosing interval as was reached in the above instance at the start of the dosing interval. However, in this situation there is no excessive BP fall as we move along the plateau part of the curve, allowing an effect on BP that persists for 24 h.
T:P ratios were introduced initially as a safety measure to prevent excessive BP falls. The problem in clinical practice is the reverse. In clinical practice BP is usually measured close to the time of peak response and the question is whether the effect will persist until the next dose. Thus a T:P ratio is needed together with its variance for all doses to determine if control is obtained. Alternatively the effectiveness of 24 h control may be determined by other means. response and a plateau (C 2 AB 2 ) effect. Whether titrated at peak or trough (post or pre-dose) the same plasma level point A will be reached. If titrated at peak the plasma level of both drugs will decline and the response pre-dose may be inadequate if the half-life is less than the dose interval. If titrated at trough (pre-dose) the response differs. For the drug with the linear relationship the plasma concentration will rise excessively (extent depends on half-life) and an excessive fall in BP results (B 1 ). For the drug with the plateau response the concentration rises, but due to the plateau the fall in BP is not excessive (B 2 ). This increased drug concentration may allow drugs with a short half-life to be given once-daily if titrated at trough when they have a plateau effect.
Alternative procedures
If the T:P ratio has many difficulties and problems, can information related to 24-h drug duration be obtained by other methods? These are summarised in Table 1 . One possible alternative is the 'missed dose response'. 1 A monitor is fitted and medication is taken at 8.00 am. The next day the patient misses the usual dose (ideally a matching placebo should be taken) and the monitor is removed at 2.00 pm. The BP 3-6 h after dosing is compared with that at 27-30 h. The difference is the amount of BP fall that does not persist for 24 h or more. If a 'placebo' A second alternative procedure is to compare the 24-h ABPM profile with a fixed dose of a drug given in the morning (say 9.00 am) or the evening (9.00 pm).
14 This is suitable for patients in whom BP has been controlled in a separate study. Patients are randomised to receive medication at 09.00 am or 9.00 pm for 1 month and then crossed over to the other therapy. ABPM is done at the end of each period. The response on the two doses is compared. If there is true 24-h control there should be no difference between the responses on the 09.00 am or 9.00 pm dose. This procedure corrects for placebo, circadian variation and also for different pharmacodynamic responses that may be associated with different times of drug administration. If a placebo ABPM had also been performed this allows assessment of the BP effect of the drug. A variant is to compare the effect of the 9.00 am dose with the same dose given both at 9.00 am and 9.00 pm. This is a rigorous test of 24-h duration of action but is appropriate mainly for drugs where the plateau (E max ) effect is reached. A further variant is to compare the effect of a fixed dose of a drug with the maximum dose of a drug which has been shown to have a T:P of 1.00.
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The above procedures are suitable for evaluation purposes and in general would be best done in responders. However, certain other approaches can be used in clinical practice and in evaluation. Home BP measurements may be taken in the morning (predose) at a fixed time at least 30 min after arising and at a fixed time in the evening on both placebo and the active drug. 16 Multiple readings are obtained. Both the morning and evening fall in BP may be determined. BP could also be measured at a fixed time interval after dosing if a peak effect was required. The advantages of this technique are the large number of measurements possible and relative standardisation of the measurement conditions, without spurious 'white coat' or other clinic effects.
Finally, in management of an individual the T:P ratio is relevant only for the decision regarding the drug and an appropriate dose to be used. Unless the drug is being used in a dose that has a T:P ratio Ͼ0.7 a check should be made that BP is controlled at trough. Usually the drug will have been titrated on a post-dose BP close to the t max . Once control has been achieved instruct the patient to attend at the next visit without having taken his medication. This will enable determination if BP has been controlled over 24 h without an ABPM. This gives similar information to the 'missed dose' ABPM technique stated above.
Conclusion
T:P ratio is a useful parameter to determine whether a drug is potentially able to cause a fall in BP that persists for 24 h. However, its limitations must be recognised. A drug that reduces BP in a group of patients by 10 mm Hg with a small variance does not enable that drug to be used without measuring BP in individual patients, as some may not respond. Likewise a drug with a T:P close to 1.0 even with a small variance does not mean that in all patients the peak response will persist for 24 h. Thus the information obtained from a T:P ratio enables selection of a drug and its dose which is most likely to give 24-h BP control, but whether this is achieved in an individual patient must be checked.
Because most antihypertensive drugs are now taken once daily, it is important to determine the 24-h effect at different doses. A 24-h T:P ratio of 1.00 for a drug titrated predose (at trough) does not mean that when that drug is titrated post dose, as is usual in practice, that BP will be controlled for 24 h. The T:P ratio is not a unique feature of a drug and within many drugs has a marked dose dependency.
To optimise the value of a T:P ratio of a drug it is important to know the variance of such a value in patients in whom the drug will be used. Thus the ratio should be calculated for an individual who has responded to the drug at peak, and then averaged for the responding group. Non-responders will not be treated with this drug and their exclusion from T:P calculation is commonsense and is not statistically flawed.
Alternative procedures to demonstrate 24-h BP control exist, and may be preferred to the T:P ratio. These techniques avoid calculation of BP responses that are dependent on different control BP throughout the day and can also correct more appropriately for circadian variation, intra-individual variation and differences in pharmacodynamics of a drug in relation to time of administration.
Missing individual doses is a common feature of management of chronic disease. Data should be collected for all drugs to assess how long it takes for BP to rise to untreated levels, or even worse to an overshoot of BP. Self measurement of BP under clearly defined conditions may be the most appropriate technique to measure over days the duration of action of an antihypertensive agent.
In summary, the T:P ratio enables the selection and use of a drug in a dose that is likely to have a similar response at the time of trough and peak effects. Practical and theoretical aspects of methodology of measurement limit the value of the ratio as a measure of drug pharmacodynamics or for the treatment prediction in an individual patient. The pattern of measurement should be standardised for compliance with requirements of drug regulatory authorities. If an individual patient has had their medication titrated and adjusted on peak response, we suggest that at a subsequent visit they should omit the morning dose so that the full extent of antihypertensive control can be determined.
